Stock·NYSE·Basic Materials
Freeport-McMoRan Inc. (FCX)
- Market cap
- $100.61B
- P/E
- 35.93
- Dividend yield
- 0.86%
- Street target
- $80.00median of 23 analysts
- 52-week range
- $38.54 $80.24
The short version
Where FCX stands today, in four lines, and what CleaRank Financial AI makes of it.
FCX at a glance
Freeport-McMoRan Inc. (FCX): Buy, 75/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($64.68 and $72.04).
- Earnings FCX beat estimates in 8 of its last 8 quarters, yet fell the next day after 6 of those beats.
- Insiders Insiders sold $46.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 35.9 against 30.2 for the Basic Materials sector: broadly in line with peers (+19%).
Figures as of October 16, 2026.
CleaRank Financial AI
Freeport-McMoRan Inc. (FCX) is currently trading at $69.63, below its 50-day simple moving average of $72.04 but above its 200-day simple moving average of $64.68.
The company's shares have seen a notable increase in analyst price targets, with a median of $80.00, indicating a potential upside of 14.9%. This positive outlook is supported by strong forward-looking estimates, with analysts projecting revenue growth of 16.00% for the current year and 20.00% for the next year, alongside an impressive 36.1% EPS growth estimate for next year. Despite the positive analyst sentiment and growth projections, recent insider activity shows a moderate sell signal, with $46.4 million in sales versus no reported purchases. The company also pays a modest dividend yield of 0.86%. The current trading price below the 50-day SMA suggests some near-term technical weakness, but the overall fundamental picture and analyst conviction remain strong.
Only on CleaRank
Figures we compute ourselves from FCX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $69.63 is 3.3% below the 50-day simple moving average of $72.04.Price above its 200-day average ›
The price is 7.6% above the 200-day simple moving average of $64.68.50-day average above the 200-day ›
The 50-day average ($72.04) is 11.4% above the 200-day average ($64.68), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 75% of its 52-week range, between $38.54 and $80.24.
FCX share price
Pick a period: each tab shows how far FCX has moved over it, to the last close.
Today's trading
Where FCX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 35.93 is 19.0% above the Basic Materials median of 30.2.P/S below the sector median ›
The price-to-sales ratio of 3.89 is 7.4% below the sector median of 4.2.Profitable over the last 12 months ›
Net income over the last 12 months was $2.9B on revenue of $25.9B, a net margin of 11.3%.Beat estimates in most recent reports ›
FCX beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 0.86%, or $0.6 a share a year.
Key statistics
The headline figures for FCX.
As of October 16, 2026, FCX trades at $69.63, with a market value of $100.61B, a P/E ratio of 35.93 and a dividend yield of 0.86%.
What the numbers say
CleaRank Financial AI's reading of FCX's valuation, growth and risks.
Freeport-McMoRan Inc. (FCX) exhibits a mixed valuation profile, with a P/E ratio of 35.93, which is higher than the sector average P/E of 30.2.
However, its Price-to-Sales ratio of 3.89 is slightly below the sector average of 4.2, and its Return on Equity (ROE) of 14.76% is below the sector median of 17.9%. The company's debt-to-equity ratio stands at 0.32, which is in line with the sector average of 0.32. The company's profit margin of 11.39% and operating margin of 33.40% demonstrate solid profitability. Analysts project significant revenue growth of 16.00% for the current year and 20.00% for the next, coupled with strong EPS growth estimates, suggesting that the current valuation may be justified by future expansion. The company's balance sheet appears healthy with a manageable debt level.
FCX against the Basic Materials sector
How FCX compares with the median Basic Materials stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (19% difference), suggesting fair market pricing relative to industry standards.
Return vs XLB: Since May 5, 2025, FCX has gained 87.6% against a gain of 20.0% for XLB.
Performance against XLB
FCX and the Basic Materials sector fund over the same days.
Revenue and earnings
How much FCX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 1.8% in FY2025 to $25.9B, from $25.5B a year earlier.
Profit margin: The net margin was 16.0% in FY2025, down from 17.3% the year before.
Profitable: FCX earned $4.2B in FY2025.
Earnings reality check
Did FCX beat what analysts expected, and how did the stock react?
Earnings record: FCX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 6 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $0.62 | $0.74 | +19.35% | -1.42% | -0.09% |
| Apr 23, 2026after close | $0.47 | $0.57 | +21.28% | -0.70% | -6.02% |
| Jan 22, 2026after close | $0.32 | $0.47 | +46.88% | +2.65% | +10.67% |
| Oct 23, 2025after close | $0.41 | $0.50 | +21.95% | +0.34% | +1.21% |
| Jul 23, 2025after close | $0.44 | $0.54 | +22.73% | -0.58% | -12.71% |
| Apr 24, 2025after close | $0.23 | $0.24 | +4.35% | -0.74% | -3.24% |
| Jan 23, 2025after close | $0.22 | $0.31 | +40.91% | -1.79% | -4.83% |
| Oct 22, 2024after close | $0.37 | $0.38 | +2.70% | -1.26% | -4.04% |
As of October 16, 2026, FCX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 6 of those beats; its latest report, on July 23, 2026, came in 19.35% above the estimate and the stock moved -1.42% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 43.8, in neutral territory.RSI above 50 ›
An RSI of 43.8 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of FCX
The score, the reasoning behind it, and what could move the price next.
Freeport-McMoRan Inc. (FCX) is trading at $69.63, below its 50-day simple moving average of $72.04 and its 20-day exponential moving average of $71.48, indicating near-term downward pressure.
The 14-day Relative Strength Index (RSI) is at 43.76, signaling neutral momentum. The MACD is at -0.24, also suggesting a lack of strong directional conviction. Key support is observed around the 200-day simple moving average at $64.68, which has acted as a floor for the stock. Resistance is present at the 50-day SMA ($72.04) and the 20-day EMA ($71.48). The chart structure indicates a consolidation phase, with potential for a breakout or breakdown depending on future catalysts.
Strong Earnings Beat Continues ›
FCX has consistently exceeded EPS estimates, most recently by 19.35% for the quarter reported July 23, 2026. This trend suggests strong operational performance and favorable market conditions.
Source: Company Earnings ReportsPositive Analyst Sentiment and Price Targets ›
The median analyst price target of $80.00 represents a 14.9% upside from the current price, supported by 23 analysts maintaining a 'Buy' consensus.
Source: Wall Street AnalystsProjected Strong Revenue and EPS Growth ›
Analysts forecast significant revenue growth of 16.00% this year and 20.00% next year, with EPS growth projected at 78.2% this year and 36.1% next year.
Source: Wall Street Estimates
Moderate Insider Selling Signal ›
Insiders have sold $46.4 million worth of stock, indicating a moderate sell signal and potentially cautious sentiment from management.
Source: Insider Transaction DataTrading Below Key Moving Averages ›
The stock is currently trading below its 50-day SMA ($72.04) and 20-day EMA ($71.48), suggesting near-term technical weakness.
Source: Technical Analysis Data
- The stock is currently trading below its 50-day SMA, suggesting potential near-term weakness. Investors may consider waiting for a confirmed break above this level for a more favorable entry point.
Technical indicators
Momentum and trend for FCX, from its daily closes.
As of October 16, 2026, with FCX at $69.63, its 14-day RSI is 43.8 (neutral territory), its 50-day simple moving average is $72.04 and its 200-day is $64.68.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What FCX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, FCX's 1-year correlation of daily returns is +0.58 with S&P 500 (SPY), +0.58 with Nasdaq 100 (QQQ), +0.31 with Bitcoin (BTC) and +0.44 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
18 of 23 analysts rate it a buy or strong buy, 4 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $80.00 is 14.9% above the price.More buy ratings than three months ago ›
18 of 23 rate it a buy now, against 19 of 23 three months ago.
FCX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | UBS | Maintains | Buy |
| Oct 7, 2026 | JP Morgan | Maintains | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Oct 6, 2026 | Barclays | Maintains | Overweight |
| Oct 6, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 5, 2026 | Citigroup | Maintains | Buy |
As of October 16, 2026, 23 Wall Street analysts cover FCX: 18 rate it a buy or strong buy, 4 a hold and 1 a sell or strong sell. Their 12-month price targets range from $30.00 to $92.00, with a median of $80.00, 14.9% above the price of $69.63.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
FCX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from FCX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much FCX tends to move, against the market and on its own.
The long record
FCX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 2.31% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 70.1%, from January 2018 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
59% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $79,698, against $42,525 in the S&P 500 (SPY).
FCX Drawdowns & Recovery
As of October 16, 2026, FCX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -70.1% (January 2018 to March 2020); it regained that peak by November 2020, 8 months after the low, and 59% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into FCX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: FCX beat the S&P 500 over this period: $79,698 against $42,525.
A $10,000 investment in FCX in October 2016 would be worth about $79,698 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to FCX, and which have not.
Strongest month, November: an average of +11.72%, up in 6 of 10 years.
Weakest month, March: an average of -3.80%, up in 3 of 10 years.
This month, October: has averaged +1.93%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, FCX's strongest calendar month has been November (average +11.72%, up in 6 of 10 years) and its weakest March (average -3.80%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in FCX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in FCX today could grow to about $27,281 by 2036 in the base case, with a 90th-percentile outcome near $192,996 and a 10th-percentile outcome around $3,856. The simulation models price only; at today's 0.86% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
FCX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $104 for FCX by 2030 in the base case, from $69.63 today (1.5x over 4 years). The 10th-percentile path ends near $30.18. These are outcomes of a Monte Carlo simulation run on FCX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $41.47 | $76.98 | $143 | |
| 2028 | $35.48 | $85.11 | $204 | |
| 2029 | $32.22 | $94.09 | $275 | |
| 2030 | $30.18 | $104 | $359 | |
| 2031 | $28.83 | $115 | $459 |
Method: a lognormal simulation of FCX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. FCX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
FCX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought FCX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, FCX insiders reported 13 open-market sales worth $46.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Hugh N Grant
Director
|
Grant | 482 | $33.7K |
| Oct 1, 2026 | John Joseph Stephens
Director
|
Grant | 294 | $20.6K |
| Aug 27, 2026 | Lydia H Kennard
Director
|
Sell | 3.8K | $300.5K |
| Aug 25, 2026 | Douglas Nicholas Currault II
General Counsel
|
Sell | 80.0K | $6.3M |
| Aug 25, 2026 | Douglas Nicholas Currault II
General Counsel
|
Option | 80.0K | $1.2M |
| Aug 5, 2026 | Stephen T Higgins
Officer
|
Sell | 14.3K | $992.3K |
| Aug 5, 2026 | Ellie L. Mikes
Officer
|
Sell | 4.8K | $334.1K |
| Jul 30, 2026 | Stephen T Higgins
Officer
|
Sell | 7.6K | $475.7K |
| Jul 1, 2026 | Hugh N Grant
Director
|
Grant | 536 | $33.7K |
| Jul 1, 2026 | John Joseph Stephens
Director
|
Grant | 327 | $20.6K |
| Jun 1, 2026 | David P Abney
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Marcela E. Cpa Donadio
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Hugh N Grant
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Lydia H Kennard
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Ryan Michael Lance
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Sara Grootwassink Lewis
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Dustan E Mccoy
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | John Joseph Stephens
Director
|
Grant | 2.8K | - |
| Jun 1, 2026 | Frances Fragos J.d. Townsend
Director
|
Grant | 2.8K | - |
| Apr 1, 2026 | Hugh N Grant
Director
|
Grant | 574 | $33.7K |
| Apr 1, 2026 | John Joseph Stephens
Director
|
Grant | 350 | $20.6K |
| Mar 6, 2026 | Richard C Adkerson
Chairman of the Board
|
Grant | 27.7K | - |
| Feb 20, 2026 | Stephen T Higgins
Officer
|
Sell | 29.7K | $1.9M |
| Feb 18, 2026 | Ellie L. Mikes
Officer
|
Sell | 11.0K | $682.3K |
| Feb 13, 2026 | Maree E Robertson
Chief Financial Officer
|
Sell | 48.5K | $3.0M |
| Feb 11, 2026 | Richard C Adkerson
Chairman of the Board
|
Sell | 401.0K | $25.5M |
| Feb 11, 2026 | Douglas Nicholas Currault II
General Counsel
|
Sell | 75.0K | $4.8M |
| Feb 11, 2026 | Douglas Nicholas Currault II
General Counsel
|
Option | 75.0K | $892.3K |
| Feb 10, 2026 | Maree E Robertson
Chief Financial Officer
|
Grant | 43.9K | - |
| Feb 9, 2026 | Richard C Adkerson
Chairman of the Board
|
Grant | 275.6K | - |
| Feb 9, 2026 | Douglas Nicholas Currault II
General Counsel
|
Grant | 34.6K | - |
| Feb 9, 2026 | Stephen T Higgins
Officer
|
Grant | 38.6K | - |
| Feb 9, 2026 | Ellie L. Mikes
Officer
|
Grant | 18.0K | - |
| Feb 9, 2026 | Kathleen L. Quirk
Chief Executive Officer
|
Grant | 179.5K | - |
| Dec 31, 2025 | Hugh N Grant
Director
|
Grant | 664 | $33.7K |
| Dec 31, 2025 | John Joseph Stephens
Director
|
Grant | 406 | $20.6K |
| Dec 11, 2025 | Stephen T Higgins
Officer
|
Sell | 28.4K | $1.4M |
| Dec 11, 2025 | Ellie L. Mikes
Officer
|
Sell | 9.6K | $456.2K |
| Nov 28, 2025 | Richard C Adkerson
Chairman of the Board
|
Grant | 28.8K | - |
| Oct 1, 2025 | Hugh N Grant
Director
|
Grant | 860 | $33.7K |
| Oct 1, 2025 | John Joseph Stephens
Director
|
Grant | 525 | $20.6K |
| Aug 25, 2025 | Richard C Adkerson
Chairman of the Board
|
Grant | 25.7K | - |
| Jul 1, 2025 | Hugh N Grant
Director
|
Grant | 778 | $33.7K |
| Jul 1, 2025 | John Joseph Stephens
Director
|
Grant | 475 | $20.6K |
| Jun 2, 2025 | Ellie L. Mikes
Officer
|
Sell | 8.6K | $343.5K |
| May 30, 2025 | David P Abney
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Marcela E. Cpa Donadio
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Robert W Dudley
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Hugh N Grant
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Lydia H Kennard
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Ryan Michael Lance
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Sara Grootwassink Lewis
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Dustan E Mccoy
Director
|
Grant | 4.9K | - |
| May 30, 2025 | John Joseph Stephens
Director
|
Grant | 4.9K | - |
| May 30, 2025 | Frances Fragos J.d. Townsend
Director
|
Grant | 4.9K | - |
| May 12, 2025 | Richard C Adkerson
Chairman of the Board
|
Grant | 44.8K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.